Tiziana Life Sciences to Spin Out IL-6R Monoclonal Antibody TZLS-501

Tiziana Life Sciences plans to spin out its fully human anti-IL-6 receptor monoclonal antibody, TZLS-501, into a separate publicly traded company. The move aims to enhance strategic focus and drive value for shareholders. Tiziana shareholders will retain value from TZLS-501 through the distribution of shares in the new entity. The decision was based on industry interest in the IL-6 pathway, highlighted by Novartis' $1.4 billion acquisition of Tourmaline Bio.